HLS Therapeutics®

Poised for High Growth

Q2 2023 Conference Call

Craig Millian, CEO

Tim Hendrickson, CFO

TSX - HLS

Forward-looking statements

Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “project”, “forecast”, “target”, “expect”, “seek”, “endeavour”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, should, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of known and unknown risks and uncertainties which would cause actual results or events to differ materially from those presently anticipated. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this presentation are based upon what HLS currently believes to be reasonable assumptions, HLS cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, HLS does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

- **All figures in USD unless otherwise noted.**
- **Historical financials are per HLS filed quarterly and annual statements**
- **Forward-looking financial estimates are converted at an exchange rate of $1.33 or 1 CAD = USD 0.75**

Leadership / Structural Changes

Executive Changes

Craig Millian
appointed CEO & Director

Brian Walsh
appointed SVP &
Head of Commercial

Board Changes

John Welborn
appointed Chair

Christian Roy, Craig Millian and John Hanna joined the board

Board size reduced from ten to eight members

Shifted return of capital to shareholders from dividend to share buyback

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

Vascepa: Continued Prescription Growth

Weekly script data since launch



91% increase in total prescriptions*

*(*Q2 2023 compared to Q2 2022)*

96% increase in prescribers*

139% increase in consistent prescribers*

*(*Q2 2023 compared to Q2 2022)*

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

Source: Weekly Rx, 2020 - 2023, IQVIA

Vascepa Outlook

2023 Vascepa revenue target

C$18-20M

Vascepa positive direct contribution to Adjusted EBITDA in

2H 2024

1  **Adapt go-to-market model**

2  **Improve reimbursement dynamics**

3  **Generate balanced payer mix**

Prioritizing 3 areas to generate sustained growth and brand profitability

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

Adjusted EBITDA Contribution (for the year-to-date period ended June 30, 2023)



Objective:

Vascepa begins to generate positive direct contribution to Adjusted EBITDA in the 2H 2024

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

HLS Therapeutics®

Poised for High Growth

Q2 2023 Conference Call

Craig Millian, CEO

Tim Hendrickson, CFO

TSX - HLS